| Literature DB >> 32269617 |
Zheng-Yang Chen1, Nan Jiang1,2, Song Guo1,2, Bin-Bin Li2,3, Jia-Qi Yang1,2, Shao-Bin Chai2, Hong-Feng Yan2, Pei-Ming Sun2, Tao Zhang2, Hong-Wei Sun2, He-Ming Yang2, Jin-Lian Zhou4, Yan Cui2.
Abstract
The understanding into the pathogenesis and treatment of gastric cancer has improved in recent years; however, a number of limitations have delayed the development of effective treatment. Cancer cells can undergo glycolysis and inhibit oxidative phosphorylation in the presence of oxygen (Warburg effect). Previous studies have demonstrated that a rotary cell culture system (RCCS) can induce glycolytic metabolism. In addition, the potential of regulating cancer cells by targeting their metabolites has led to the rapid development of metabolomics. In the present study, human HGC-27 gastric cancer cells were cultured in a RCCS bioreactor, simulating weightlessness. Subsequently, liquid chromatography-mass spectrometry was used to examine the effects of simulated microgravity (SMG) on the metabolism of HGC-27 cells. A total of 67 differentially regulated metabolites were identified, including upregulated and downregulated metabolites. Compared with the normal gravity group, phosphatidyl ethanolamine, phosphatidyl choline, arachidonic acid and sphinganine were significantly upregulated in SMG conditions, whereas sphingomyelin, phosphatidyl serine, phosphatidic acid, L-proline, creatine, pantothenic acid, oxidized glutathione, adenosine diphosphate and adenosine triphosphate were significantly downregulated. The Human Metabolome Database compound analysis revealed that lipids and lipid-like metabolites were primarily affected in an SMG environment in the present study. Overall, the findings of the present study may aid our understanding of gastric cancer by identifying the underlying mechanisms of metabolism of the disease under SMG. Copyright: © Chen et al.Entities:
Keywords: HGC-27; PA; PC; PE; PS; RCCS; SM; SMG; metabolism
Year: 2020 PMID: 32269617 PMCID: PMC7115135 DOI: 10.3892/ol.2020.11451
Source DB: PubMed Journal: Oncol Lett ISSN: 1792-1074 Impact factor: 2.967
Figure 1.Metabolite-concentration distribution in HGC-27 gastric cancer cells under NG and SMG using PLS-DA. (A) Total NG for 1 and 3 days vs. total SMG for 1 and 3 days. (B) NG for 1 day vs. SMG for 1 day. (C) NG for 3 days vs. SMG for 3 days. (D) SMG for 1 day vs. SMG for 3 days. PLS-DA, partial least squares discriminate analysis; NG, normal gravity; SMG, simulated microgravity; D1, 1 day duration; D3, 3 day duration; Comp, component.
Figure 2.Human Metabolme Database compound classification analysis of the significantly altered metabolites indicating that lipids were the mo st influenced metabolite under simulated microgravity. 1, Glycerophospholipids (45.1%); 2, Fatty Acids (13.73%); 3, Carboxylic acids and derivatives (7.84%); 4, Prenol lipids (5.88%); 5, Sphingolipids (5.88%); 6, Organonitrogen Compounds (3.92%); 7, Organooxygen compounds (3.92%); 8, Alcohols and polyols (1.96%); 9, Carbonyl compounds (1.96%); 10, Flavonoids (1.96%) and 11, Others (7.85%).
Quantitated lipid classes and numbers in HGC-27 cells under normal gravity and simulated microgravity.
| Lipid category | Lipid class | Number of lipid species |
|---|---|---|
| Phospholipid | Phosphatidylcholine | 13 |
| Lysophospholipid | 1 | |
| Glycerophosphocholine | 1 | |
| Phosphatidylethanolamine | 12 | |
| Phosphatidylserine | 3 | |
| Phosphatidic acid | 1 | |
| Sphingolipid | Sphingomyelin | 2 |
| Sphinganine | 1 | |
| Oleamide | 1 | |
| Linoleamide | 1 | |
| Dihydroceramide | 1 | |
| Lactosylceramide | 1 | |
| Glycerolipide | Glycinoprenol 9 | 1 |
| Other lipids | Umbelliprenin | 1 |
| Sorbitan stearate | 1 | |
| Pantothenic Acid | 1 | |
| Oleoylcarnitine | 1 | |
| Isobutyryl carnitine | 1 | |
| Glycocholic acid | 1 | |
| Camelliagenin B | 1 | |
| Arachidonic acid | 1 | |
| 8-Hydroxyguanosine | 1 | |
| 3-Hydroxyhexadecanoyl carnitine | 1 | |
| 2-Methylbutyroylcarnitine | 1 | |
| Total lipids | 50 |
Identification of the significantly altered metabolites in HGC-27 cells.
| Metabolite | Formula | M/Z | P-value | Regulation | VIP |
|---|---|---|---|---|---|
| SM (d18:+B5:G321/14:0) | C37H75N2O6P | 719,5313 | 8.951×10−6 | Downregulated | 1,5850 |
| SM [d18:0/16:1(9Z)] | C39H79N2O6P | 747,5634 | 2.004×10−2 | Downregulated | 1,8047 |
| PS [DiMe(11,3)/MonoMe(11,5)] | C47H80NO12P | 918,4877 | 1.500×10−8 | Downregulated | 1,1943 |
| PS [18:3(9Z,12Z,15Z)/22:1(13Z)] | C46H82NO10P | 822,5620 | 9.948×10−3 | Downregulated | 1,2988 |
| PS [14:1(9Z)/24:0] | C44H84NO10P | 800,5760 | 1.440×10−7 | Downregulated | 3,0884 |
| PE-NMe2 [14:1(9Z)/16:1(9Z)] | C37H70NO8P | 732,4793 | 2.400×10−8 | Downregulated | 3,9878 |
| PE-NMe [14:1(9Z)/16:1(9Z)] | C36H68NO8P | 718,4649 | 4.190×10−6 | Downregulated | 1,0028 |
| PE (15:0/P-16:0) | C36H72NO7P | 706,4990 | 1.223×10−6 | Upregulated | 1,8137 |
| PE [15:0/24:1(15Z)] | C44H86NO8P | 832,6037 | 4.555×10−3 | Upregulated | 1,3361 |
| PE [15:0/22:5(4Z,7Z,10Z,13Z,16Z)] | C42H74NO8P | 796,5100 | 7.155×10−4 | Upregulated | 1,4220 |
| PE [15:0/22:4(7Z,10Z,13Z,16Z)] | C42H76NO8P | 798,5255 | 2.232×10−2 | Upregulated | 1,3835 |
| PE [15:0/22:2(13Z,16Z)] | C42H80NO8P | 802,5564 | 1.816×10−2 | Downregulated | 2,8050 |
| PE [15:0/22:1(13Z)] | C42H82NO8P | 804,5728 | 7.846×10−5 | Upregulated | 4,1810 |
| PE [15:0/20:2(11Z,14Z)] | C40H76NO8P | 774,5259 | 9.433×10−6 | Downregulated | 8,3376 |
| PE [15:0/18:2(9Z,12Z)] | C38H72NO8P | 746,4948 | 1.153×10−6 | Downregulated | 4,9712 |
| PE [14:0/24:1(15Z)] | C43H84NO8P | 818,5870 | 9.771×10−6 | Upregulated | 1,1963 |
| PE [14:0/20:2(11Z,14Z)] | C39H74NO8P | 757,5542 | 4.356×10−3 | Downregulated | 2,1212 |
| PC [o-16:0/20:4(8Z,11Z,14Z,17Z)] | C44H82NO7P | 812,5771 | 1.832×10−2 | Upregulated | 1,2528 |
| PC [22:5(4Z,7Z,10Z,13Z,16Z)/16:0] | C46H82NO8P | 852,5716 | 4.918×10−2 | Upregulated | 2,0817 |
| PC [22:4(7Z,10Z,13Z,16Z)/14:0] | C44H80NO8P | 826,5566 | 7.767×10−6 | Upregulated | 3,9909 |
| PC [18:4(6Z,9Z,12Z,15Z)/P-18:0] | C44H80NO7P | 810,5616 | 3.320×10−7 | Upregulated | 2,0711 |
| PC [18:4(6Z,9Z,12Z,15Z)/P-16:0] | C42H76NO7P | 782,5270 | 1.608×10−5 | Upregulated | 1,0437 |
| PC [18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)] | C48H82NO8P | 876,5722 | 2.134×10−4 | Upregulated | 1,7139 |
| PC [18:0/20:4(5Z,8Z,11Z,14Z)] | C46H84NO8P | 854,5879 | 9.655×10−6 | Upregulated | 1,5839 |
| PC [18:0/18:2(9Z,12Z)] | C44H84NO8P | 830,5881 | 6.867×10−4 | Upregulated | 2,3650 |
| PC [16:1(9Z)/20:3(5Z,8Z,11Z)] | C44H80NO8P | 826,5554 | 1.198×10−4 | Upregulated | 1,5843 |
| PC [16:1(9Z)/16:1(9Z)] | C40H76NO8P | 752,5196 | 2.971×10−2 | Downregulated | 4,8632 |
| PC [16:0/20:5(5Z,8Z,11Z,14Z,17Z)] | C44H78NO8P | 824,5400 | 9.291×10−3 | Upregulated | 3,4401 |
| PC [16:0/20:3(5Z,8Z,11Z)] | C44H82NO8P | 826,5554 | 6.358×10−3 | Upregulated | 1,4770 |
| PC (16:0/18:3(6Z,9Z,12Z)] | C42H78NO8P | 800,5412 | 9.244×10−4 | Upregulated | 2,2188 |
| PA (16:0/18:1(11Z)] | C37H71O8P | 719,4839 | 4.759×10−6 | Downregulated | 1,2779 |
| LysoPC [20:4(8Z,11Z,14Z,17Z)] | C28H50NO7P | 588,3274 | 5.778×10−5 | Upregulated | 1,7989 |
| Sphinganine | C18H39NO2 | 302,3052 | 6.998×10−3 | Upregulated | 2,7342 |
| Oleamide | C18H35NO | 563,5495 | 7.274×10−4 | Upregulated | 31,6443 |
| Linoleamide | C18H33NO | 280,2632 | 1.702×10−2 | Upregulated | 10,9674 |
| Lactosylceramide (d18:1/12:0) | C42H79NO13 | 850,5563 | 5.000×10−9 | Upregulated | 3,5254 |
| Glycerophosphocholine | C8H20NO6P | 258,1098 | 1.328×10−2 | Upregulated | 1,5225 |
| Dihydroceramide | C19H39NO3 | 362,3264 | 2.622×10−2 | Upregulated | 1,9767 |
VIP, variable importance; M/Z, mass-to-charge ratio; SM, sphingomyelin; PS, phosphatidylserine; PE, phosphatidylethanolamine; PC, phosphatidylcholine; PA, phosphatidic acid; LysoPC, lysophosphatidylcholine.
Figure 3.Effects of SMG on the expression of (A) SM (d18:1/14:0), (B) PE [15:0/20:2(11Z,14Z)], (C) PE [16:1(5Z)/16:1(5Z)], (D) PE-NMe2 [14:1(9Z)/16:1(9Z)], (E) PS [14:1(9Z)/24:0], (F) Glucosylceramide (d18:1/18:0), (G) Lactosylceramide (d18:1/12:0) and (H) PE [15:0/18:2(9Z,12Z)]. *P<0.05, **P<0.01 and ***P<0.001. NG, normal gravity; SMG, simulated microgravity; D1, 1 day duration; D3, 3 day duration; PE, phosphatidyl ethanolamine; SM, sphingomyelin.
Figure 4.Effects of SMG on the expression of (A) 3-hydroxyhexadecanoyl carnitine, (B) Isobutyayl carnitine, (C) 2-Methylbutyroylcarnitine, (D) Oleoylcarbitine, (E) ATP and (F) ADP. *P<0.05, **P<0.01 and ***P<0.001. NG, normal gravity; SMG, simulated microgravity; D1, 1 day duration; D3, 3 day duration; ATP, adenosine triphosphate; ADP, adenosine diphosphate.
Figure 5.Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis of the significantly dysregulated metabolites with SMG. x-axis is the -log10(P-value). **P<0.01 and ***P<0.001. FoxO, forkhead box O.